Key result
Supplementation with EGCG and 60 mL coconut oil daily for 4 months reduced WHtR and fat mass while increasing PON1 and albumin in MS patients.
Why the study?
Multiple sclerosis causes anthropometric changes linked to increased cardiac risk, and the impact of intervention with EGCG and ketone bodies on this risk needed evaluation.
Does supplementation with epigallocatechin gallate (EGCG) and coconut oil added to an isocaloric diet improve anthropometric and biochemical markers of cardiac risk in patients with multiple sclerosis?
RCT (n=51)
Placebo-controlled (for EGCG capsules)
Randomisation without stratification by drawing sealed, opaque envelopes arranged in a computer-generated random order
Does supplementation with epigallocatechin gallate (EGCG) and coconut oil added to an isocaloric diet improve anthropometric and biochemical markers of cardiac risk in patients with multiple sclerosis?
In this pilot RCT of 51 patients with multiple sclerosis, a 4-month supplementation with EGCG and coconut oil improved surrogate anthropometric measures (WHR, WHtR, fat and muscle mass) and serum antioxidant/anti-inflammatory biomarkers (PON1, albumin) associated with cardiovascular risk.
Answers are grounded in this paper and cite their sources.
May support EGCG-coconut oil as adjunct for cardiac risk markers in MS; extends pilot RCT evidence on metabolic interventions in neuroinflammation.
Multiple sclerosis (MS) is a neurodegenerative disease that causes anthropometric changes characterised by functional disability, increase in fat mass, and decrease in lean mass. All these variables are related to a greater cardiac risk. The polyphenol epigallocatechin gallate (EGCG) and an increase in ketone bodies in the blood have been shown to have beneficial effects on anthropometric and biochemical variables related to cardiovascular activity. The aim of this study was to analyse the impact of the intervention with EGCG and ketone bodies on cardiac risk in MS patients. A population of 51 MS patients were randomly assigned to a control group and an intervention group (daily dose of 800 mg of EGCG and 60 mL of coconut oil). Both groups followed an isocaloric diet for 4 months. Levels of beta-hydroxybutyrate (BHB), albumin, paraoxonase 1 (PON1) and C-reactive protein (CRP) were measured in serum before and after the intervention, as well as determining functional ability, waist circumference, waist-to-hip ratio (WHR), waist-to-height ratio (WHtR), fat percentage and muscle percentage. After 4 months, in the intervention group there was a significant increase in BHB, PON1 and albumin, while CRP did not vary; a significant decrease in cardiac risk associated with a significant decline in WHR; as well as a significant increase in muscle percentage. By contrast, these changes were not observed in the control group. Finally, results from analysis of variance (ANOVA) revealed a significant time-condition interaction effect, observing that WHtR and fat mass decreased in the intervention group, while they increased in the control group.
No takes yet. Share an insight, caveat, or question.
Benlloch et al. (2020) conducted an RCT in Multiple sclerosis (n=51). Epigallocatechin gallate (EGCG) and extra virgin coconut oil with an isocaloric diet vs. Isocaloric diet without coconut oil plus matching microcrystalline cellulose placebo capsules was evaluated on Anthropometric and biochemical cardiovascular risk markers (WHR-based cardiac risk, WHtR, fat mass, muscle mass, serum BHB, albumin, PON1, and CRP) (p=0.001). Supplementation with EGCG and 60 mL coconut oil daily for 4 months reduced WHtR and fat mass while increasing PON1 and albumin in MS patients.
Synapse has enriched 10 related papers. Consider them for comparative context: